ПОВОЛЖСКИЙ ОНКОЛОГИЧЕСКИЙ ВЕСТНИК 1( 28)’ 2017
2. Wilson M., Rosato E. L., Chojnacki K. A. et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer // J. Surg. Res.— 2008.— 146.— P. 11-15.
3. Burmeister B. H., Smithers B. M., Gebski V., et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial // Lancet Oncol.— 2005.— 6.— P. 659-68.
4. Tepper J., Krasna M. J., Niedzwiecki N., et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 // J. Clin. Oncol.— 2008.— 26.— P. 1086-92.
5. Van Hagen P., Hulshof M. C., van Lanschot J. J., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer // N. Engl. J. Med.— 2012.— 366.— P. 2074-84.
6. Ancona E., Ruol A., Santi S., et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone // Cancer.— 2001 June 1.— 91( 11).— P. 2165-74.
7. Kato H., Fukuchi M., Manda R, et al. The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas // Anticancer Res.— 2004 Nov-Dec.— 24( 6).— P. 4091-6.
8. Berger A. C., Farma J., Walter J. Scott, W. J. et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival // Journal of Clinical Oncology.— July 2005.— 23, № 19.— P. 4330-4337.
9. Donahue J. M., Nichols F. C, Li Z. et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival // Ann. Thorac. Surg.— 2009 Feb.— 87( 2).— P. 392-399.
10. Meredith K. L., Weber J. M., Turaga K. K. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer // Ann. Surg. Oncol.— 2010 Apr.— 17( 4).— P. 1159-67.
11. Dittrick G. W., Weber J. M., Shridhar R., et al. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrated no survival benefit compared with patients treated with primary esophagectomy // Ann. Surg. Oncol.— 2012.— 19.— P. 1678-84.
12. Hsu P., Chien L., Huang C. et al. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all? // Surgery.— 2013 Sep.— 17( 3).— P. 460-466.
13. McGlone E. R., Khan O. A. Prognostic benefit of surgery following chemoradiotherapy for squamous cell carcinoma of the oesophagus // International Journal of Surgery.— Vol. 10, Is. 7.— P. 341-344.
14. Bedenne L., Michel P., Bouche O. et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 // Journal of clinical oncology.— April 2007.— 25, № 10.— P. 1160-1168.
15. Stahl M., Stuschke M., Lehmann N., et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus // J. Clin. Oncol.— 23.— 2310.— P. 2005-2317.
16. Swisher S. G., Maish M., Erasmus J. J. et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer // The annals of thoracicsurgery.— Осtоber 2004.— Vol. 78, Is. 4.— P. 1152-1160.
17. Kim T. J., Kim H. Y., Lee K. W. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy // RadioGraphycs.— March-April 2009.— Vol. 29.— P. 403-421.
18. Westerterp M., van Westreenen H. L., Reitsma J. B. et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy— systematic review // Radiology.— 2005.— 236.— P. 841-851.
19. Therasse P., Arbuck S. G., Eisenhauer E. A. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada // J. Natl. Cancer Inst.— 2000.— 92( 3).— P. 205-216.
20. Лавникова Г. А. Некоторые закономерности лучевого патоморфоза опухолей человека и их практическое использование // Вестн. АМН СССР.— 1976.— 6.— С. 13-19.
21. Bollschweiler E., Holscher A. H., Schmidt M. and Warnecke-Eberz U. Neoadjuvant treatment for
М. В. Аглуллина и соавт. Эффективность рентгенологической и эндоскопической оценки ответа опухоли... 9